72071-62-6

Upstream product

• 213192-58-6 3-amino-3-(4-acetamidophenyl)propionic acid 
• 122-85-0 para-acetamidobenzaldehyde 
• 72071-61-5 3-Hydroxyamino-3-(4-nitro-phenyl)-propionic acid 

Downstream Products

• 551964-58-0 t-Butyl {N'-[(3R/S)-t-butoxycarbonylamino-3-(4-t-butoxycarbonylaminophenyl)propionyl]-N-methylhydrazino}acetate 
• 551964-59-1 {N'-[3-amino-3-(4-amino-phenyl)-propionyl]-N-methyl-hydrazino}-acetic acid 
• 551964-57-9 (3R/S)-t-butoxycarbonylamino-3-(4-t-butoxycarbonylaminophenyl)propionic acid 

Relevant academic research and scientific papers

Conformationally restricted analogs of deoxynegamycin

Deoxynegamycin (1b) is a protein synthesis inhibitor with activity against Gram-negative (GN) bacteria. A series of conformationally restricted analogs were synthesized to probe its bioactive conformation. Indeed, some of the constrained analogs were found to be equal or better than deoxynegamycin in protein synthesis assay (1b, IC50=8.2μM; 44, IC 50=6.6μM; 35e2, IC50=1μM). However, deoxynegamycin had the best in vitro whole cell antibacterial activity (Escherichia coli, MIC=4-16μg/mL; Klebsiella pneumoniae, MIC=8μg/mL) suggesting that other factors such as permeation may also be contributing to the overall whole cell activity. A new finding is that deoxynegamycin is efficacious in an E. coli murine septicemia model (ED50=4.8mg/kg), providing further evidence of the favorable in vivo properties of this class of molecules.

Beta-amino acid derivatives useful for the treatment of bacterial infections

The invention provides compounds that are useful for the treatment of bacterial infections in mammals. More specifically, it is directed to beta-amino acid derivatives or pharmaceutically acceptable salts, prodrugs, or isomers of those compounds that are